Tissue-Resident T Cells: Sequestered immune sensors and effectors of inflammation in Spondyloarthritis.
Despite a ballooning therapeutic tool box, treatment responses to newer biologic agents and oral small molecules in psoriatic arthritis (PsA) and spondyloarthritis (SpA) are of similar magnitude to those observed with anti-Tumor Necrosis Factor (TNF) medications (1, 2).The PsA and SpA therapeutic outcomes stand in marked contrast to those reported in psoriasis where blockade of molecules in the IL-23/IL-17 pathway often provide prolonged, deep responses and in some cases even remission (3). The underlying mechanisms that account for these divergent outcomes in the skin and joint are not well understood and are the subject of much speculation centered primarily on the existence of distinct cell populations or disease pathways unique to the joint.